What Vimian Group does

Vimian Group AB is a Stockholm-based global animal health company operating through four business segments: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics. Founded in 2021 and listed on Nasdaq Stockholm (moved to the Main Market in 2025), the company serves veterinary professionals and animal health clinics across 80 markets with approximately 1,300 employees. The portfolio is delivered through five wholly-owned operating subsidiaries — Nextmune (allergy diagnostics and treatment), Movora (surgical and orthopedic products), Indical Bioscience (diagnostics and bioscience), VetFamily (veterinary practice services), and Heiland (veterinary products) — plus recently acquired brands I-Vet, Biofleet, Vet-Allergy, Kahu Vet Group, and AllAccem. In FY2025, Vimian reported EUR 425.0 million in revenue and EUR 105.3 million in adjusted EBITA (13% and 11% growth, respectively), launched 94 new products, and educated 65,000 veterinary professionals.

The company runs an acquisition-driven platform model: it integrates specialty animal health businesses under a single corporate umbrella while preserving acquired brand identities, and grows them through shared distribution, R&D, and professional training. Its go-to-market is B2B, distributing products and services directly to veterinary clinics and animal health professionals. Revenue mechanics blend one-time product sales (MedTech surgical products and equipment, Specialty Pharma products) with recurring subscription revenue from the Veterinary Services platform (serving 10,900 member clinics) and reference laboratory diagnostic services. The Q4 2025 organic revenue growth of 6% and EUR 17.5 million revenue contribution from five new businesses added during 2025 illustrate the balance between organic and inorganic growth.

Vimian finances its growth through capital markets: a 2024 rights issue and a EUR 150 million senior unsecured bond issuance in May 2025 (within a EUR 250 million framework). Recent corporate actions include the appointment of Alireza Tajbakhsh as CEO in November 2025, the March 2026 appointment of Lotta Lundaas as Head of Medtech, and the spring 2026 departure of long-tenured Specialty Pharma head Magnus Kjellberg. The company also received EUR 28.7 million in full payment from a U.S. indemnification dispute and achieved an AAA sustainability rating in May 2026.

Name

Vimian Group

Legal name

Vimian Group AB (publ)

Website

https://vimian.com

Company type

Public

Founded year

2021

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Vimian Group AB is a Stockholm-based global animal health company operating four segments — Specialty Pharma, MedTech, Veterinary Services, and Diagnostics — serving veterinary clinics and professionals across 80 markets through wholly-owned subsidiaries and an integrated B2B platform.

Ownership category

akta.pro rank

Product category

Animal Health Products and Services

NAICS

Veterinary Services (54194), Veterinary Services (541940), Support Activities for Animal Production (11521)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047)

akta.pro primary industry

Veterinary Distributor Value-Added Services (3PL, Cold Chain, Returns) (HLAMAIAG)

akta.pro secondary industry

Specialty Veterinary Therapeutics Distribution (Oncology, Dermatology, Endocrinology) (HLAMAIAH)

Keywords

• Animal health products
• Veterinary pharmaceuticals
• Veterinary medical devices
• Animal diagnostics services
• Veterinary practice services

Headquarters

HQ city

Stockholm

HQ country

Sweden

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Product Sales - Specialty Pharma: Revenue from pharmaceutical products for animal health sold to veterinary professionals and clinics
2. Product Sales - MedTech: Revenue from veterinary surgical products and medical equipment sold to veterinary clinics
3. Veterinary Services: Subscription-style platform services to member veterinary clinics with recurring revenue
4. Diagnostic Services: Reference laboratory and diagnostic testing services for companion animals

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Vimian is a global animal health company that develops, manufactures, and distributes veterinary pharmaceuticals, medical technology products, diagnostic services, and practice-support services through four segments — Specialty Pharma, MedTech, Veterinary Services, and Diagnostics — serving veterinary professionals and clinics across 80 markets. The company combines proprietary products with a 10,900-member clinic services platform and extensive professional training programs to grow acquired specialty businesses globally.

Product overview

Vimian Group is a global animal health company operating as a platform of four core segments: Specialty Pharma, MedTech, Veterinary Services, and Diagnostics. The company has grown through acquisitions of specialized brands including Nextmune (allergy products), Movora (surgical/orthopedic products), VetFamily (practice management services), Indical (bioscience diagnostics), I-Vet and Biofleet (Italian diagnostics), Vet-Allergy (Danish allergy diagnostics), and Kahu Vet Group (surgical products in ANZ). The Veterinary Services platform serves approximately 10,900 member clinics. The company generated EUR 425 million in revenues in 2025 with operations across 80 markets.

Differentiator

Problem solved

Functional benefit

Brands

• Nextmune: Animal health - allergy diagnostics and treatment
• Movora
• Indical Bioscience
• VetFamily
• Heiland

Products and services

• Specialty Pharma Pharmaceutical products for animal health conditions, including specialty medications for companion and production animals, sold to veterinary professionals and clinics.
• MedTech Medical technology products for veterinary use, including surgical instruments, orthopedic implants, and devices for veterinary procedures, sold to veterinary clinics.
• Veterinary Services Subscription-style practice management services, professional networks, and support platforms for veterinary clinics, currently serving approximately 10,900 member clinics.
• Diagnostics Companion animal diagnostic services including reference laboratory testing and diagnostic solutions sold to veterinary clinics and professionals.
• Nextmune Animal health allergy diagnostics and treatment products and services within Vimian's Specialty Pharma portfolio.
• Movora Veterinary surgical products and orthopedic solutions provider within Vimian's MedTech segment.
• VetFamily Veterinary services platform providing practice management support, professional education, and business services to veterinary clinics (10,900 member clinics).
• Indical Bioscience Bioscience diagnostics products and services for animal health, including molecular and reference laboratory diagnostic kits.
• I-Vet (Italian Diagnostics) Italian companion animal diagnostic services provider, with reference laboratory and diagnostic services reaching approximately 5,000 veterinary clinics across Italy.
• Vet-Allergy Veterinary allergy diagnostics and treatment solutions provider in Denmark, serving over 300 veterinary clinics.
• Kahu Vet Group Veterinary surgical products supplier operating in New Zealand and Australia, with reported 2021 revenues of approximately EUR 8.5 million.

Quantifiable outcome

• EUR 425 million in revenues (2025), a 13% increase from prior year
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered minor.

• Franzini FamilyminorOthers · 27 March 2026The Franzini family sold I-Vet srl and Biofleet srl to Vimian Group. I-Vet was founded in 2012 and generates approximately EUR 5.6 million in annual revenue with 75 employees serving around 5,000 veterinary clinics across Italy. This was Vimian's fifth strategic transaction of the year 2026.
• I-VetminorStrategic or Co-development Partner · 12 February 2026I-Vet is a leading provider of companion animal diagnostics in Italy. Vimian signed agreement to acquire I-Vet in December 2025, with acquisition completed in March 2026. I-Vet serves 5,000 veterinary clinics and offers reference laboratory and diagnostic services with annual revenues of around EUR 5.6 million.
• Vet-AllergyminorStrategic or Co-development Partner · 7 February 2022Vet-Allergy is a veterinary allergy company in Denmark acquired by Vimian to enhance its position in veterinary allergy diagnostics and treatment in Scandinavia. The company serves over 300 veterinary clinics and is the leading provider of veterinary allergy solutions in Denmark.
• Kahu Vet GroupminorStrategic or Co-development Partner · 3 February 2022Kahu Vet Group is a veterinary surgical product supplier in New Zealand and Australia acquired by Vimian as part of its geographic expansion strategy. The company had revenues of approximately EUR 8.5 million in 2021. Purchase price was EUR 12.1 million upfront with potential earn-outs of up to EUR 10.4 million based on performance.

Scale indicators15 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Zoetis: Zoetis is the world's largest pure-play animal health company, spanning pharma, diagnostics, and devices across companion and livestock. It is the dominant incumbent against which Vimian competes in Specialty Pharma and Diagnostics, with materially larger R&D and global reach.
• IDEXX Laboratories: IDEXX is the leading companion animal diagnostics company globally, with reference lab services (IDEXX Reference Laboratories) and in-clinic analyzers. It is the most direct large-scale competitor to Vimian's Diagnostics segment and a benchmark for recurring vet-channel economics.
• Elanco Animal Health: Elanco is a diversified animal health company with pharma and pet health portfolios (including the acquired Bayer Animal Health). It overlaps with Vimian's Specialty Pharma and MedTech segments and competes in similar veterinary channels.
• Henry Schein Animal Health (Covetrus heritage): Henry Schein's animal health business (which absorbed Covetrus) is one of the largest distributors of veterinary products in North America. It is comparable to Vimian's B2B distribution model across MedTech and pharma products.
• Mars Petcare / Antech Diagnostics: Mars Petcare owns Antech Diagnostics (reference labs) and Banfield/BluePearl veterinary hospital chains. It is comparable to Vimian's Diagnostics and Veterinary Services segments at much larger scale, with vertically integrated veterinary care delivery.

Direct peers

• Virbac: Virbac is an independent animal health company specializing in veterinary pharmaceuticals, particularly specialty/specialty categories like dermatology, parasiticides, and aquaculture. It is closely comparable to Vimian's Specialty Pharma and allergy businesses (Nextmune).
• Vetoquinol: Vetoquinol is a French independent animal health company focused on specialty pharma (orthopedics, dermatology, cardiology). Like Vimian, it pursues a specialty, non-commoditized positioning in veterinary pharma with mid-sized global scale.
• Dechra Pharmaceuticals: Dechra was a UK-listed specialty veterinary pharma company acquired by Elanco in 2024; it served as a directly comparable specialty-pharma-and-services platform prior to acquisition and represents the archetype Vimian is emulating in its roll-up strategy.
• Phibro Animal Health: Phibro is a US-listed animal health and nutrition company with specialty pharma (nutritional health, vaccines) and a similarly mid-cap scale. It overlaps with Vimian's Specialty Pharma positioning and B2B distribution to veterinarians.

Emerging players

• Pharmgate Animal Health: Pharmgate is a privately held specialty animal health company focused on parasiticides and therapeutic solutions for livestock and companion animals. It is comparable as a smaller, specialty-focused animal health platform similar to Vimian's Specialty Pharma positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A5 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vimian Group